Ask Warren

Daewoong Pharma

069620 · KOSPI · ₩069620 · 대웅제약

₩101,100▼ ₩400 (0.39%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩448B₩378B₩397B₩412B₩405B₩356B₩368B₩358B
Cost of sales₩199B₩197B₩187B₩198B₩190B₩173B₩178B₩176B
Gross profit₩249B₩181B₩210B₩214B₩215B₩183B₩190B₩182B
Operating income₩68B₩22B₩43B₩57B₩58B₩39B₩39B₩37B
Net income₩20B₩26B₩86B₩47B₩40B₩20B−₩4.9B₩30B
Net income to shareholders₩33B₩26B₩90B₩46B₩38B₩22B−₩13B₩28B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩2.5T₩2.5T₩2.4T₩2.3T₩2.1T₩2T₩2T₩1.9T
Current assets₩761B₩738B₩732B₩790B₩707B₩622B₩613B₩574B
Cash and equivalents₩155B₩164B₩169B₩204B₩160B₩98B₩103B₩95B
Total liabilities₩1.3T₩1.3T₩1.2T₩1.3T₩1.2T₩1.1T₩1T₩971B
Current liabilities₩860B₩657B₩589B₩684B₩636B₩590B₩629B₩538B
Borrowings₩397B₩898B₩827B₩791B₩731B₩663B₩646B₩586B
Total equity₩1.2T₩1.2T₩1.1T₩1T₩954B₩930B₩927B₩951B
Shareholders' equity₩1.1T₩1T₩1T₩880B₩832B₩804B₩795B₩817B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩47B₩17B₩40B₩58B₩48B₩3.1B₩23B₩22B
Capital spending₩44B₩74B₩90B₩59B₩23B₩20B₩48B₩31B
Free cash flow₩3.5B−₩57B−₩49B−₩1.2B₩25B−₩17B−₩26B−₩8.7B
Dividends paid₩6.9B₩978M₩9M₩1.2B₩0₩6.9B₩7.8M₩447M

Consolidated where available. Amounts in won.

Also known as: Daewoong Pharma / 대웅제약 / 069620 / KRX:069620

Source: KRX statistical information